Roivant Sciences Ltd. 8-K/A

What Happened
Roivant Sciences Ltd. (ROIV) filed an amendment to a previously filed Form 8-K on March 23, 2026 to disclose that it entered into a Material Definitive Agreement — a Settlement Agreement dated March 3, 2026. The amendment states that, except for the disclosure in this filing, no other changes were made to the original 8-K and that this amendment should be read together with the original filing.

Key Details

• Settlement Agreement dated March 3, 2026 is submitted as Exhibit 10.1 to the amended 8-K.
• Portions of Exhibit 10.1 are redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K (non-material, confidential terms).
• Certain exhibits and schedules to the Settlement Agreement were omitted pursuant to Item 601(a)(5) of Regulation S-K.
• Filing date of the amendment: March 23, 2026 (amends an earlier 8-K).

Why It Matters
A disclosed settlement agreement under Item 1.01 indicates Roivant has entered into a material contractual arrangement that the company believes is important for investors to know. While key commercial or financial terms are redacted in the public exhibit, investors should note the company formally documented and filed the agreement and watch for any future filings (e.g., additional disclosures or unredacted summaries) that provide more detail on potential financial impacts, obligations, or changes resulting from the settlement.